论文部分内容阅读
（目的）观察P170糖蛋白表达与原发性肝癌对肝动脉化疗栓塞（TACE）治疗反应性的相关性。[方法]采用单克隆抗体免疫细胞化学方法检测47例TACE治疗前肝癌病人的癌细胞P170表达。[结果]P170阳性率74．5％（35／47）。P170阳性组35例经TACE治疗AFP下降50%以上的出现率为25.0％．明显低于P170阴性组12例的70.0%1（P＜0.05）。P170阳性组有效率25．7％，低于P170阴性组的50．0％（P＞0．05）。〔结论〕P170对测定为估计肝癌TACE治疗敏感性的有效指标。
(Objective) To observe the correlation between P170 glycoprotein expression and the response of primary liver cancer to hepatic arterial chemoembolization (TACE). [Methods] The expression of P170 in 47 cases of liver cancer patients before TACE treatment was detected by monoclonal antibody immunocytochemistry. [Results] The positive rate of P170 was 74.5% (35/47). In the P170-positive group, the incidence of AFP decreased by more than 50% in TACE treatment was 25.0%. It was significantly lower than that of 70.0%1 in 12 cases of P170 negative group (P<0.05). The effective rate of P170 positive group was 25.7%, which was lower than that of P170 negative group (50.0%) (P>0.05). [Conclusion] P170 is an effective index for estimating the sensitivity of TACE treatment in liver cancer.